7380 related articles for article (PubMed ID: 23818364)
1. Correlation of nuclear morphometry of primary melanoma of the skin with clinicopathological parameters and expression of tumor suppressor proteins (p53 and p16(INK4a)) and bcl-2 oncoprotein.
Mijovic Z; Kostov M; Mihailovic D; Zivkovic N; Stojanovic M; Zdravkovic M
J BUON; 2013; 18(2):471-6. PubMed ID: 23818364
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin.
Talve L; Kainu J; Collan Y; Ekfors T
Pathol Res Pract; 1996 Aug; 192(8):825-33. PubMed ID: 8897518
[TBL] [Abstract][Full Text] [Related]
3. Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.
Kostov M; Mijović Z; Mihailović D; Cerović S; Stojanović M; Jelić M
Bosn J Basic Med Sci; 2010 Nov; 10(4):276-81. PubMed ID: 21108607
[TBL] [Abstract][Full Text] [Related]
4. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract][Full Text] [Related]
6. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
[TBL] [Abstract][Full Text] [Related]
7. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
10. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
11. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma.
Miracco C; Santopietro R; Biagioli M; Lazzi S; Nyongo A; Vatti R; Luzi P
J Cutan Pathol; 1998 May; 25(5):244-51. PubMed ID: 9696289
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prognostic characteristics of stage I cutaneous malignant melanoma.
Tan GJ; Baak JP
Anal Quant Cytol; 1984 Sep; 6(3):147-54. PubMed ID: 6508033
[TBL] [Abstract][Full Text] [Related]
13. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
14. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of combined h-TERT, bcl-2, and caspases 3 and 8 expression in cutaneous malignant melanoma based on tissue microarrays and computerized image analysis.
Zygouris P; Tsiambas E; Tiniakos D; Karameris A; Athanassiou AE; Kittas Ch; Kyroudi A
J BUON; 2007; 12(4):513-9. PubMed ID: 18067210
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
[TBL] [Abstract][Full Text] [Related]
17. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.
Fujiwaki R; Hata K; Iida K; Maede Y; Watanabe Y; Koike M; Miyazaki K
Acta Obstet Gynecol Scand; 1999 Sep; 78(8):728-34. PubMed ID: 10468067
[TBL] [Abstract][Full Text] [Related]
19. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
20. [Immunomorphological features of cutaneous basal-cell carcinoma].
Chuprov IN
Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
